Do serum angiogenic growth factors provide additional information to that of conventional markers in monitoring the course of metastatic breast cancer?

Anna Maria Granato, Giovanni Luca Frassineti, Noemi Giovannini, Michela Ballardini, Oriana Nanni, Roberta Maltoni, Dino Amadori, Annalisa Volpi

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: Our work evaluated the potential role of basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) serum levels with respect to that of conventional serum tumour markers, CEA and CA 15-3, in monitoring the course of metastatic breast cancer in 56 female patients treated with cytotoxic chemotherapy. Methods: VEGF and bFGF concentrations were determined using a quantitative sandwich enzyme immunoassay technique. The positive predictive value (PPV) of each marker and of marker combinations for different types of clinical response was calculated. Results: The highest PPV for overall disease control was shown by bFGF (70%), which also showed the highest PPV for both partial response (36.4%) and stable disease (63.2%). CEA showed the highest predictive value for progression (69.2%). A combined increase in CEA and bFGF or VEGF was associated with disease progression in all patients. Conclusions: Information provided by angiogenic factor levels seems to be independent of and is possibly complementary to that provided by conventional serum markers. bFGF showed the maximum predictive value for disease control and provided additional information to that obtained from CEA or CA 15-3 evaluation. It could therefore be a promising candidate for monitoring response to chemotherapy in advanced breast cancer.

Original languageEnglish
Pages (from-to)302-308
Number of pages7
JournalTumor Biology
Volume27
Issue number6
DOIs
Publication statusPublished - Oct 2006

Keywords

  • Angiogenic serum markers
  • Breast cancer, advanced
  • Disease monitoring

ASJC Scopus subject areas

  • Cancer Research

Fingerprint Dive into the research topics of 'Do serum angiogenic growth factors provide additional information to that of conventional markers in monitoring the course of metastatic breast cancer?'. Together they form a unique fingerprint.

Cite this